Clinical Trials and Tribulations

FromI AM BIO

Start listening View podcast show

Clinical Trials and Tribulations

FromI AM BIO

ratings:

Length:

29 minutes

Released:

Aug 3, 2020

Format:

Podcast episode

Description

As Moderna breaks the record for speed in starting the final stage of human testing for its covid vaccine, new BIO CEO Dr. Michelle McMurry-Heath tackles the thorny issue of how to best structure the historic Phase 3 clinical trial. The Boston biotech’s Chief Medical Officer reveals the strategy to test vaccine efficacy on communities of color and others hardest hit by the coronavirus.

Hosted by Dr. Michelle McMurry-Heath

Released:

Aug 3, 2020

Format:

Podcast episode

Titles in the series (100)

Powerful stories of biotechnology breakthroughs, the people they help, and the global problems they solve. Hosted by BIO President & CEO Dr. Michelle McMurry-Heath.

Skip carousel

Destroying COVID's Genome: Alnylam Pharmaceuticals, which take its name from the center and brightest star in Orion’s Belt, is working on an RNAi therapy to destroy the genome of the novel coronavirus — and with it, its ability to replicate and kill. Hosted by Jim Greenwood. by I AM BIO
39 min listen
“Herd” Immunity (Redux): Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
The Antibody Test Shortage: Only antibody testing can tell us who has been infected and recovered from coronavirus and when it might be safe to return to work. There’s a massive global shortage of these tests, and a Maryland biotech is racing to bolster the U.S. supply. Hosted by Jim Greenwood. by I AM BIO
27 min listen
An Alternative to Flying Dirty: While Swedish climate activist Greta Thunberg has kindled a global dialogue about the ravages of climate change and the role of airline emissions, a Colorado biotech is putting forward a jaw-dropping alternative to flight shaming: actual jet fuel with no carbon footprint. Hosted by Jim Greenwood. by I AM BIO
40 min listen
COVID-19 Could Generate 1st Computerized Vaccine: Futuristic biotech Moderna is the first to clinically test a coronavirus vaccine, created in weeks using only the virus’ genetic code. The company’s messenger RNA breakthrough may be just in time as a former CDC director warns that animal viruses spilling over to humans is the new normal. Hosted by Jim Greenwood. by I AM BIO
60 min listen
First Dose: One day before 16-year-old Izzy Thorpe-Wall takes her first dose of Vertex’s stunning Cystic Fibrosis breakthrough, Thorpe and her mother, Clare, open up about their emotional journey and one brave girl’s determination to stay healthy long enough to meet this day of her dreams. Hosted by Jim Greenwood. by I AM BIO
43 min listen
COVID-19: We Were Warned: For years, leaders on the Bipartisan Commission on Biodefense told Congress and the White House that it wasn’t a matter of if, but when, a pandemic would happen. Exploring the panel’s unheeded recommendations can give the United States a blueprint for what to do going forward to protect us from the coronavirus and future threats. Hosted by Jim Greenwood. by I AM BIO
50 min listen
Going Viral: Vir Biotechnology CEO George Scangos is the scientist selected by his peers to lead the biotechnology industry’s efforts to mitigate and ultimately end the pandemic. He explains how and why the novel coronavirus is so contagious and potentially dangerous to millions. Hosted by Jim Greenwood. by I AM BIO
23 min listen
COVID-19’s True Origins: There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Coronavirus Lung Treatment Could be Ready In Weeks: Regeneron’s rheumatoid arthritis drug shows promise to treat coronavirus-related lung syndrome and stop the inflammation that leads to death. The company also expects to test a preventative antibody shot in June. Hosted by Jim Greenwood. by I AM BIO
40 min listen
“Herd” Immunity: Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
New Trailer with Dr. Michelle: The I AM BIO podcast with host Dr. Michelle McMurry-Heath explores the search for biotechnology breakthroughs and our progress in ending the pandemic, helping patients and carrying the mantle for science and sustainability. by I AM BIO
2 min listen
Biotech's Finest Hour (Redux): As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
48 min listen
What Can Iceland Tell Us About COVID?: The people of Iceland — a country of 360,000 — eagerly volunteered for genetic research on how the coronavirus affects a homogeneous population. Amgen’s work in the Land of Fire and here at home could deliver answers and antibodies to help mitigate the pandemic threat. Hosted by Jim Greenwood. by I AM BIO
32 min listen
COVID’s Essential Work: The physician-wife of Roivant Sciences CEO Vivek Ramaswamy rushed back to the front lines at the pandemic’s peak — less than a month after giving birth to the couple’s first son. Meanwhile, dad cared for their newborn while testing a promising therapeutic that seeks to overcome deadly cytokine storms caused by the novel coronavirus. Hosted by Jim Greenwood. by I AM BIO
30 min listen
Biotech’s Finest Hour: As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
53 min listen
Trying our Patients: As genetic sequencing gives scientists new tools to hone in on medical mysteries, Washington politicians flirt dangerously with policies that would stymie the genomic revolution while giving patients scant pricing relief at the pharmacy counter. Hosted by Jim Greenwood. by I AM BIO
36 min listen
COVID-19’s True Origins (Redux): There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Superbuggin’: Incurable gonorrhea and the deadly hospital superbug C. diff offer a frightening window into the gathering public health menace of antibiotic resistance. If society doesn’t wake up and tackle the problem, we could be headed toward a calamity on the magnitude of climate change. Hosted by Jim Greenwood. by I AM BIO
28 min listen
COVID & the Plastics Problem: Fear and misinformation about how the coronavirus is transmitted has led to dangerous backsliding in society’s efforts to address plastic pollution. But we don’t have to lose this battle to win the COVID war. A Georgia biotech is first to market with a green biopolymer material that looks and feels like plastic but dissolves in ocean water. Hosted by Jim Greenwood. by I AM BIO
32 min listen
COVID X-FACTOR: The diversity of our adaptive immune system is why people are reacting so differently to the novel coronavirus. No two people present the virus the exact same way to their immune systems. We’ve evolved in this way as humans to ensure no virus can eradicate our species. Hosted by Jim Greenwood. by I AM BIO
32 min listen
Cancer in the COVID Era: Overcrowded hospitals during the pandemic can pose treatment challenges for patients with other serious illnesses. As Kite Pharma CEO Christi Shaw says, “Cancer doesn’t stop in a crisis.” Neither do her company’s employees, who go to extraordinary lengths to get personalized CAR-T treatments to patients around the world. Hosted by Jim Greenwood. by I AM BIO
20 min listen
Vaccines are a Virtue: As biotech researchers work around the clock on a covid vaccine, ill-informed, anti-science anti-vaxxers must be denounced and excoriated in the public square. BIO’s head of infectious disease policy Phyllis Arthur administers a vital dose of vaccine education, because none of us is safe until we all are. Hosted by Jim Greenwood. by I AM BIO
33 min listen
Sickle Cell Saviors: Need a dose of inspiration in a time of national tragedy? A remarkable biotech breakthrough from Global Blood Therapeutics offers fresh hope to patients living with sickle-cell disease. Hosted by Jim Greenwood. by I AM BIO
62 min listen
The Other Pandemic: Beating “Nightmare Bugs” (Part 2 of 2): Viral pandemics can lead to secondary bacterial infections that kill millions, Dr. Anthony Fauci concluded after studying the 1918 Spanish flu. A century later, COVID and antibiotic resistance are proving to be a lethal combination. What are the biopharma industry and Congress doing to keep your loved ones safe from superbugs? Hosted by Jim Greenwood. by I AM BIO
32 min listen
Vaccine Velocity: How can global nonprofits like the Center for Epidemic Preparedness Innovations (CEPI) deliver a safe and effective vaccine against the novel coronavirus in just 12 to 18 months when the world record for vaccine approval is four years? CEPI CEO Richard Hatchett, a 9/11 hero, says it’s all about smart planning. By the time governments give the green light on the safety and efficacy of a covid vaccine, manufacturer capacity will be pre-scaled up and able to quickly churn out doses by the tens or hundreds of millions. Hosted by Jim Greenwood. by I AM BIO
33 min listen
BONUS: Breaking Barriers in Trade: A Conversation with Dr. Ngozi Okonjo-Iweala: We are on summer break as we work to bring you another exciting season this fall. So, for the next few weeks we’re sharing some of our favorite sessions from the June 2021 BIO Digital. Today, check out our session Breaking Barriers in Trade: A Conversation with Dr. Ngozi Okonjo-Iweala, Director-General, World Trade Organization. Speaker: Dr. Ngozi Okonjo-Iweala, World Trade Organization by I AM BIO
33 min listen
Respiratory Rescue?: The engine powering Maryland vaccine maker Novavax is a recombinant nanoparticle platform that is impressing vaccinologists as well as government and nonprofit funders. Learn about the innovative biotech generating big buzz in the global covid vaccine race. by I AM BIO
28 min listen
Can We Pass This COVID Test?: Millions of travelers ignored public health warnings and packed into airports over the holidays to see their loved ones. As a result, U.S. hospitals are bracing for the deadliest COVID surge yet this month. Meanwhile, Sherlock Biosciences, which has already made history once with CRISPR, seeks to do so again with an inexpensive, accurate home test that could be a global game-changer. by I AM BIO
36 min listen
Deep Diving for COVID Cures: By studying our earliest evolutionary ancestors in the ocean, marine biotech researchers are gaining fresh insights about everything from anti-virals to coronavirus nasal swab testing to the inner workings of our adaptive immune systems. Learn what sea sponges, lugworms and sharks can teach us about improving human health during this crisis. Hosted by Jim Greenwood. by I AM BIO
43 min listen

More Episodes from I AM BIO

Skip carousel

Listener takeover: Your Biotech Questions Answered: YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from you, our listeners. We discuss topics ranging from the safety of genetically modified foods (GMOs), to the new era of personalized medicine, feeding the world by 2050, and even what makes start-up companies attractive to investors. by I AM BIO
21 min listen
Editing Cells Within the Body—a New CRISPR Frontier: With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body. We discuss the progress and the challenge in making this breakthrough a reality. by I AM BIO
21 min listen
Biotech is Climate Tech: Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech. by I AM BIO
21 min listen
Biotech for our Pets: More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries. by I AM BIO
28 min listen
What We Know About the Microbiome: The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits. by I AM BIO
27 min listen
Is CRISPR the New Sickle Cell Savior?: 2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. by I AM BIO
25 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection (REDUX): Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here (REDUX): Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death (REDUX): For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling (REDUX): The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech. (REDUX): Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab? (REDUX): The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection: Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here: Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death: For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling: The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech.: Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab?: The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
Stand Up for Science—The Fight Against Misinformation (Redux): Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech? (Redux): The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR (Redux): CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures (Redux): When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs (Redux): The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen
Cracking the Code on Pain Relief (Redux): Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies. by I AM BIO
26 min listen
Why are Katie Couric and 15K People Headed to Boston?: During the last several decades Boston has become a biotech Mecca, with its Kendall Square attracting more than 120 biotech companies, both large and small. It is called the most innovative square mile on the planet. This June BIO will bring over 15,000 biotech leaders to Boston for its 2023 BIO International Convention. Speakers including award-winning journalist and health advocate, Katie Couric, will talk about how they will “Stand up for Science”—the Convention’s theme. MassBIO CEO, Kendalle Burlin O’Connell joins host, Rachel King in a wide-ranging discussion about how Boston became the largest biotech hub in the world. by I AM BIO
16 min listen
Stand Up for Science—The Fight Against Misinformation: Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech?: The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR: CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures: When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs: The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen

Related podcast episodes

Skip carousel

Saving Lives in 3D – Lorenzo Moroni, Professor of Biofabrication, Regenerative Medicine, Maastricht University – Boundless Biofabrication: Advances in Drug Therapy and What the Future Holds for Regenerative Medicine: Kidney failure? No problem. Need a new heart? Check, working on it. Let’s just head on over to the 3D printer and print one up and send you on your way. While this sounds like science fiction, and currently still is, the advances in biofabrication... by Finding Genius Podcast
24 min listen
Our Microbiome, Cancer, and Infectious Diseases: Microbiologist Samuel Minot Runs the Numbers: A microbiologist by training, Sam Minot now works as a computational biologist helping other scientists understand the data between of human microbiome and health connections. In this podcast, he explains Why the complexity of bacteria and viruses... by Finding Genius Podcast
30 min listen
Part 2: Keeping up with the Chemos Series: Administration of Trabectedin and Doxorubicin by SGO on the GO
14 min listen
Episode 120: COVID-19 Vaccine by Newt's World
34 min listen
Next-Generation Tissue Analysis Furthering the Field of Immuno-Oncology—Brian McKelligon—Akoya Biosciences: CEO of Akoya Biosciences, Brian McKelligon, discusses how technology can improve and advance research in the field of immuno-oncology. In this episode, you will learn: How the therapies in immuno-oncology use the immune system to shut down the... by Finding Genius Podcast
25 min listen
Cancer Immunotherapy: The newest and most promising therapies for challenging cancers are adopting molecular-biology strategies. Brain tumors are especially problematic because of their location impedes patient function and presents formidable barriers to surgical treatments. by Talking Biotech with Dr. Kevin Folta
42 min listen
Testing for Cancer – Gregory Kuehn, MBA, President and COO of Prescient Metabiomics – Colon Cancer, the Microbiome, Testing: Gregory Kuehn, MBA, President and COO of Prescient Metabiomics, formerly Metabiomics, discusses their innovative work in colorectal and the development of an advanced stool test for cancer. Kuehn holds an MBA from the University of Colorado and a BS... by Finding Genius Podcast
23 min listen
Trust Your Gut: Dr. Kathy McCoy Shares Exciting Microbiome Research Discovery: Tiny microbes make a huge difference in our health. These internal ecological systems utilize communication or signaling to maintain this health, effecting immune system function. This podcast shares an important discovery in this communication that... by Finding Genius Podcast
40 min listen
Trust Your Gut: Dr. Kathy McCoy Shares Exciting Microbiome Research Discovery: Tiny microbes make a huge difference in our health. These internal ecological systems utilize communication or signaling to maintain this health, effecting immune system function. This podcast shares an important discovery in this communication that... by Finding Genius Podcast
40 min listen
Trust Your Gut: Dr. Kathy McCoy Shares Exciting Microbiome Research Discovery: Tiny microbes make a huge difference in our health. These internal ecological systems utilize communication or signaling to maintain this health, effecting immune system function. This podcast shares an important discovery in this communication that... by Finding Genius Podcast
41 min listen
Is Your Gut Microbiome Healthy, and Is Your Baby’s?—The Latest in Microbiome Research from Hein Min Tun, PhD, Public Health Veterinarian: Hein Min Tun, PhD, is a public health veterinarian and researcher who is currently leading research efforts at the University of Hong Kong School of Public Health. He discusses the details of his work, including the following: What methods are used... by Finding Genius Podcast
27 min listen
What's A Biologic Revolution? With Vaxxinity's Mei Mei Hu, J.D. by Business Of Biotech
53 min listen
Finding Balance: Microbiome and Cancer Research with Mahmoud Ghannoum: Could a saliva swab detect cancer presence? Researchers are closer than ever to using such noninvasive biomarker tests as diagnostic tools. Why? Well, it's all about balance, even at the smallest level. Researcher Mahmoud Ghannoum joins Richard to... by Finding Genius Podcast
33 min listen
Episode 14 - Mold, Mycotoxins, and Indoor Testing Methods with Dr. David Straus by Exposing Mold
61 min listen
Dr. Yug Varma - Microbiome Approach To Acne: What does microbiome reveal about acne? The different skin microbiomes all over our body How to treat acne Yug Varma, PhD, is the co-founder & CEO of Phyla, the world’s most advanced probiotic acne system. He has 10+ years of microbiome... by Beauty Wisdom Podcast
25 min listen
#69 Jackson Lab's Forum on Healthcare Innovation: Highlights from Jackson Lab’s Forum on Healthcare Innovation about genetic testing/genomics, microbiome and the new “All of Us” program. by DNA Today: A Genetics Podcast
30 min listen
Accelerating Microbiome Research for Improved Human Health—Dr. Sandrine Miller-Montgomery—UC San Diego Center for Microbiome Innovation: Dr. Sandrine Miller-Montgomery is the executive director of the UC San Diego Center for Microbiome Innovation and professor in the department of bioengineering whose aim is to understand and foster microbiome diversity and develop technologies that... by Finding Genius Podcast
33 min listen
Pneumococcal Vaccination for Adults: Conversation with Vaccine Scientists Dr. Heather Platt and Dr. Ulrike Buchwald from Merck by Xtalks Life Science Podcast
44 min listen
Breast Cancer Vaccine Update: Dr. Justin Johnson explains early results from three small studies on a vaccine for triple-negative breast cancer. by Breastcancer.org Podcast
5 min listen
The Promise of Organ-on-a-Chip Technology to Improve Drug Development: One way to improve drug discovery and development is to work with more accurate models of human biology and human disease. Organ-on-a-chip technology that provides three-dimensional cell models in conventional microfluidic plates is helping to do tha... by The Bio Report
26 min listen
Biomedical Engineering for Intratumoral Drug Delivery, Tissue Regeneration, and In Vitro Disease Modelling—Jeannine Coburn—Worcester Polytechnic Institute: You probably didn’t realize that you’re likely wearing a material that can serve as the foundation of biomaterials used for a variety of functions, including drug delivery, tissue regeneration, and in vitro disease modelling. That’s right,... by Finding Genius Podcast
35 min listen
The mRNA Vaccine Drive Is a High-Tech Holocaust Designed to Evade Scrutiny | Guest: Dr. William Makis | 9/20/23 by Conservative Review with Daniel Horowitz
61 min listen
Covid three years on: Partygate, WhatsApp, and a Lab Leak?: Three years ago this week, Boris Johnson announced a national lockdown to curb the spread of Coronavirus. But three years on, Covid and the impact of lockdowns continue to dominate our headlines. This week, Boris Johnson faced a Commons inquiry... by The Fourcast
26 min listen
MVA85A trial investigation - press conference.: Trial MVA85A - monkey trials for a booster vaccine for BCG, developed by researchers at Oxford University, is the subject of an investigation published on bmj.com. Experts warn that today’s investigation is just one example of “a systematic failure”... by The BMJ Podcast
49 min listen
SCCM Pod-489 The AIMS Trial: Battle of the Bundles, Hour-1 Versus 3-Hour: SCCM Pod-489 The AIMS Trial: Battle of the Bundles, Hour-1 Versus 3-Hour by SCCM Podcast
23 min listen
057: Undone by Fungi Again: The Mycobiome with Mahmoud Ghannoum: One reason is because the overwhelming bacterial members of the microbiome keep the fungi in check. Dr. Mahmoud Ghannoum is a professor at Case Western University and the director of the Center for Medical Mycology, who studies fungal pathogens, such... by microTalk
46 min listen
Multi-omics | The importance of science in data science: Join us for this exciting conversation with Chris Whelan of Johnson & Johnson about muli-omics. He does a phenomenal job of explaining the basics, shines a light on some of the challenges of the field, all while staying conveying the hope of what this could all mean in terms of understanding and treating disease biology. by Speaking of Mol Bio
33 min listen
COVID-19: Emerging Tests, Vaccines and Cures: As the coronavirus spreads rapidly through the population, the United States is racing to provide test kits, and develop a vaccine. Three leading experts will share where we are today, where we are headed, and what it will take to get us there. by Commonwealth Club of California Podcast
67 min listen
Key Studies on Vaccine-Preventable Diseases Influencing My Practice Following IDWeek 2021: Listen to expert insights from Martin C. Mahoney, MD, PhD, on new data for vaccine-preventable diseases presented at the IDWeek meeting, including pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza. by CCO Infectious Disease Podcast
39 min listen
Covid-19 With Virologist Dr. Christian Bréchot, Plus Rambo Goes to Venezuela: Leading virologist Dr. Christian Bréchot discusses all things Covid-19, Katie and Matt break down a failed coup attempt in Venezuela by Useful Idiots with Katie Halper and Aaron Maté
82 min listen

Discover this podcast and so much more

Clinical Trials and Tribulations

Clinical Trials and Tribulations

Description

Titles in the series (100)

More Episodes from I AM BIO

Related podcast episodes